IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-36924-z.html
   My bibliography  Save this article

Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice

Author

Listed:
  • Yoshito Yamada

    (University Hospital Zurich
    Kyoto University Graduate School of Medicine
    Chiba University Graduate School of Medicine)

  • Tuan Thanh Nguyen

    (University Hospital Zurich)

  • Daniela Impellizzieri

    (University Hospital Zurich)

  • Katsutaka Mineura

    (Kyoto University Graduate School of Medicine)

  • Rintaro Shibuya

    (Kyoto University Graduate School of Medicine)

  • Alvaro Gomariz

    (University Hospital Zurich
    Computer Vision Laboratory, ETH Zurich)

  • Martina Haberecker

    (University Hospital Zurich)

  • Jakob Nilsson

    (University Hospital Zurich)

  • César Nombela-Arrieta

    (University Hospital Zurich
    University of Zurich)

  • Wolfgang Jungraithmayr

    (University Hospital Zurich
    Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Onur Boyman

    (University Hospital Zurich
    University of Zurich)

Abstract

Transplantation of solid organs can be life-saving in patients with end-stage organ failure, however, graft rejection remains a major challenge. In this study, by pre-conditioning with interleukin-2 (IL-2)/anti-IL-2 antibody complex treatment biased toward IL-2 receptor α, we achieved acceptance of fully mismatched orthotopic lung allografts that remained morphologically and functionally intact for more than 90 days in immunocompetent mice. These allografts are tolerated by the actions of forkhead box p3 (Foxp3)+ regulatory T (Treg) cells that home to the lung allografts. Although counts of circulating Treg cells rapidly return to baseline following cessation of IL-2 treatment, Foxp3+ Treg cells persist in peribronchial and peribronchiolar areas of the grafted lungs, forming organized clusters reminiscent of inducible tertiary lymphoid structures (iTLS). These iTLS in lung allografts are made of Foxp3+ Treg cells, conventional T cells, and B cells, as evidenced by using microscopy-based distribution and neighborhood analyses. Foxp3-transgenic mice with inducible and selective deletion of Foxp3+ cells are unable to form iTLS in lung allografts, and these mice acutely reject lung allografts. Collectively, we report that short-term, high-intensity and biased IL-2 pre-conditioning facilitates acceptance of vascularized and ventilated lung allografts without the need of immunosuppression, by inducing Foxp3-controlled iTLS formation within allografts.

Suggested Citation

  • Yoshito Yamada & Tuan Thanh Nguyen & Daniela Impellizzieri & Katsutaka Mineura & Rintaro Shibuya & Alvaro Gomariz & Martina Haberecker & Jakob Nilsson & César Nombela-Arrieta & Wolfgang Jungraithmayr , 2023. "Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36924-z
    DOI: 10.1038/s41467-023-36924-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-36924-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-36924-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Rita Cabrita & Martin Lauss & Adriana Sanna & Marco Donia & Mathilde Skaarup Larsen & Shamik Mitra & Iva Johansson & Bengt Phung & Katja Harbst & Johan Vallon-Christersson & Alison Schoiack & Kristina, 2020. "Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma," Nature, Nature, vol. 580(7801), pages 1-1, April.
    2. Alvaro Gomariz & Patrick M. Helbling & Stephan Isringhausen & Ute Suessbier & Anton Becker & Andreas Boss & Takashi Nagasawa & Grégory Paul & Orcun Goksel & Gábor Székely & Szymon Stoma & Simon F. Nør, 2018. "Quantitative spatial analysis of haematopoiesis-regulating stromal cells in the bone marrow microenvironment by 3D microscopy," Nature Communications, Nature, vol. 9(1), pages 1-15, December.
    3. Rita Cabrita & Martin Lauss & Adriana Sanna & Marco Donia & Mathilde Skaarup Larsen & Shamik Mitra & Iva Johansson & Bengt Phung & Katja Harbst & Johan Vallon-Christersson & Alison Schoiack & Kristina, 2020. "Tertiary lymphoid structures improve immunotherapy and survival in melanoma," Nature, Nature, vol. 577(7791), pages 561-565, January.
    4. Beth A. Helmink & Sangeetha M. Reddy & Jianjun Gao & Shaojun Zhang & Rafet Basar & Rohit Thakur & Keren Yizhak & Moshe Sade-Feldman & Jorge Blando & Guangchun Han & Vancheswaran Gopalakrishnan & Yuanx, 2020. "B cells and tertiary lymphoid structures promote immunotherapy response," Nature, Nature, vol. 577(7791), pages 549-555, January.
    5. Florent Petitprez & Aurélien Reyniès & Emily Z. Keung & Tom Wei-Wu Chen & Cheng-Ming Sun & Julien Calderaro & Yung-Ming Jeng & Li-Ping Hsiao & Laetitia Lacroix & Antoine Bougoüin & Marco Moreira & Gui, 2020. "B cells are associated with survival and immunotherapy response in sarcoma," Nature, Nature, vol. 577(7791), pages 556-560, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Nanda Horeweg & Hagma H. Workel & Dominik Loiero & David N. Church & Lisa Vermij & Alicia Léon-Castillo & Ricki T. Krog & Stephanie M. Boer & Remi A. Nout & Melanie E. Powell & Linda R. Mileshkin & He, 2022. "Tertiary lymphoid structures critical for prognosis in endometrial cancer patients," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    3. Mattia Rediti & Aranzazu Fernandez-Martinez & David Venet & Françoise Rothé & Katherine A. Hoadley & Joel S. Parker & Baljit Singh & Jordan D. Campbell & Karla V. Ballman & David W. Hillman & Eric P. , 2023. "Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    4. Akshay J. Patel & Zena N. Willsmore & Naeem Khan & Alex Richter & Babu Naidu & Mark T. Drayson & Sophie Papa & Andrew Cope & Sophia N. Karagiannis & Esperanza Perucha & Gary W. Middleton, 2022. "Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    5. Olivia Le Saux & Maude Ardin & Justine Berthet & Sarah Barrin & Morgane Bourhis & Justine Cinier & Yasmine Lounici & Isabelle Treilleux & Pierre-Alexandre Just & Guillaume Bataillon & Aude-Marie Savoy, 2024. "Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    6. Li Yuan & Guo-Dong Jia & Xiao-Fei Lv & Si-Yi Xie & Shan-Shan Guo & Da-Feng Lin & Li-Ting Liu & Dong-Hua Luo & Yi-Fu Li & Shen-Wen Deng & Ling Guo & Mu-Sheng Zeng & Xiu-Yu Cai & Sai-Lan Liu & Xue-Song , 2023. "Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    7. Matthew T. Campbell & Surena F. Matin & Alda L. Tam & Rahul A. Sheth & Kamran Ahrar & Rebecca S. Tidwell & Priya Rao & Jose A. Karam & Christopher G. Wood & Nizar M. Tannir & Eric Jonasch & Jianjun Ga, 2021. "Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    8. Zhenzhen Xun & Xinyu Ding & Yao Zhang & Benyan Zhang & Shujing Lai & Duowu Zou & Junke Zheng & Guoqiang Chen & Bing Su & Leng Han & Youqiong Ye, 2023. "Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    9. Jae-Won Cho & Seyeon Park & Gamin Kim & Heonjong Han & Hyo Sup Shim & Sunhye Shin & Yong-Soo Bae & Seong Yong Park & Sang-Jun Ha & Insuk Lee & Hye Ryun Kim, 2021. "Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    10. Yang Liu & Shuang-Yan Ye & Shuai He & Dong-Mei Chi & Xiu-Zhi Wang & Yue-Feng Wen & Dong Ma & Run-Cong Nie & Pu Xiang & You Zhou & Zhao-Hui Ruan & Rou-Jun Peng & Chun-Ling Luo & Pan-Pan Wei & Guo-Wang , 2024. "Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-22, December.
    11. David Hsiehchen & Muhammad S. Beg & Radhika Kainthla & Jay Lohrey & Syed M. Kazmi & Leticia Khosama & Mary Claire Maxwell & Heather Kline & Courtney Katz & Asim Hassan & Naoto Kubota & Ellen Siglinsky, 2024. "The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    12. Lenka Kasikova & Jana Rakova & Michal Hensler & Tereza Lanickova & Jana Tomankova & Josef Pasulka & Jana Drozenova & Katerina Mojzisova & Anna Fialova & Sarka Vosahlikova & Jan Laco & Ales Ryska & Pav, 2024. "Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    13. Jianming Xu & Yi Li & Qingxia Fan & Yongqian Shu & Lei Yang & Tongjian Cui & Kangsheng Gu & Min Tao & Xiuwen Wang & Chengxu Cui & Nong Xu & Juxiang Xiao & Quanli Gao & Yunpeng Liu & Tao Zhang & Yuxian, 2022. "Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    14. Miles C. Andrews & Junna Oba & Chang-Jiun Wu & Haifeng Zhu & Tatiana Karpinets & Caitlin A. Creasy & Marie-Andrée Forget & Xiaoxing Yu & Xingzhi Song & Xizeng Mao & A. Gordon Robertson & Gabriele Roma, 2022. "Multi-modal molecular programs regulate melanoma cell state," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    15. Soizic Garaud & Marie-Caroline Dieu-Nosjean & Karen Willard-Gallo, 2022. "T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-4, December.
    16. Rana Falahat & Anders Berglund & Patricio Perez-Villarroel & Ryan M. Putney & Imene Hamaidi & Sungjune Kim & Shari Pilon-Thomas & Glen N. Barber & James J. Mulé, 2023. "Epigenetic state determines the in vivo efficacy of STING agonist therapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    17. Kenro Tanoue & Hirofumi Ohmura & Koki Uehara & Mamoru Ito & Kyoko Yamaguchi & Kenji Tsuchihashi & Yudai Shinohara & Peng Lu & Shingo Tamura & Hozumi Shimokawa & Taichi Isobe & Hiroshi Ariyama & Yoshih, 2024. "Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    18. Alma Andersson & Ludvig Larsson & Linnea Stenbeck & Fredrik Salmén & Anna Ehinger & Sunny Z. Wu & Ghamdan Al-Eryani & Daniel Roden & Alex Swarbrick & Åke Borg & Jonas Frisén & Camilla Engblom & Joakim, 2021. "Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    19. Martin Lauss & Bengt Phung & Troels Holz Borch & Katja Harbst & Kamila Kaminska & Anna Ebbesson & Ingrid Hedenfalk & Joan Yuan & Kari Nielsen & Christian Ingvar & Ana Carneiro & Karolin Isaksson & Kri, 2024. "Molecular patterns of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    20. Aditi Sahu & Kivanc Kose & Lukas Kraehenbuehl & Candice Byers & Aliya Holland & Teguru Tembo & Anthony Santella & Anabel Alfonso & Madison Li & Miguel Cordova & Melissa Gill & Christi Fox & Salvador G, 2022. "In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response," Nature Communications, Nature, vol. 13(1), pages 1-19, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36924-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.